Dianthus reports Q2 net loss $17.6M; cash $360.7M funds pipeline into 2H'27

Dianthus Therapeutics, Inc. /DE/

2024-Q2 EPS reported -$0.99 revenue$2,737,000

Net loss $17.6M ($0.51/share) vs $11.1M ($12.73/share) in Q2 2023.
Cash, equivalents & short-term investments $360.7M as of June 30, 2024, projected runway into 2H'27.
Phase 2 MaGic trial in gMG ongoing; top-line results expected 2H'25.
IND cleared for Phase 2 MoMeNtum trial in MMN; top-line results anticipated 2H'26.
Alison Lawton appointed Chair of Board, effective July 1, 2024, succeeding Lonnie Moulder.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.